FDA Will Not Be “Health SEC,” Chief Counsel Troy Tells Investors
This article was originally published in The Gray Sheet
Executive Summary
FDA and the Securities & Exchange Commission are making progress on formalizing communications about potentially misleading disclosures to investors, FDA Chief Counsel Dan Troy told attendees of a Schwab Washington Research Group conference May 15